The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index; 9 of the 39 sources its claims cite were checked for support.
Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease
Open accessAbstract
Minocycline is a commonly used drug for adjunctive therapy in periodontal disease. However, the current mainstream local medications primarily rely on intra‐pocket administration, which, while avoiding the side effects of traditional systemic drugs, presents challenges such as inconvenience, discomfort, and the need for professional assistance, thus affecting patient compliance. Herein, we introduce a minocycline‐loaded dissolvable microneedle (Mino‐DMN) patch that allows for local and efficient delivery of minocycline to gingiva for the treatment of periodontitis. A two‐step casting micro‐molding process involving vacuum drying and freeze drying is employed to concentrate minocycline in the microneedle part and limit its diffusion into the patch backing. The resulting Mino‐DMN patch features an array of minocycline‐enriched gelatin MNs with a porous HA patch backing. The microneedles can penetrate into gingiva with enough mechanical strength and quickly release minocycline into the gingival tissue, ensuring prolonged local residence of the drug and minimizing its loss to saliva. In vivo experiments show Mino‐DMN inhibits pro‐inflammatory factors, promotes anti‐inflammatory factors, and stimulates bone formation, surpassing topical application and comparable to the inconvenient and discomfort administration of Periocline®. This proposed Mino‐DMN offers a simple, efficient, user‐friendly strategy for the adjunctive treatment of periodontal disease.
Overview
CoChat Summary
TL;DR
A minocycline-loaded dissolvable microneedle (Mino-DMN) patch with gelatin tips and a porous hyaluronic acid backing delivers minocycline locally to gingiva and shows antibacterial, anti-inflammatory, and bone-protective effects in a rat periodontitis model. It surpasses topical minocycline and is largely comparable to Periocline® ointment, though alveolar bone loss (ABL) was significantly higher in the Mino-DMN group than in the Periocline® group.
Key findings
- The two-step casting process concentrated minocycline in the microneedle tips: actual loading was 51 ± 6 μg per patch; a solid backing caused approximately three times greater drug loss than the porous backing, and sucrose-containing HA backing had a modulus approximately three times higher than pure HA backing.
- Microneedles sustained approximately 0.13 N per tip before fracturing, achieved 100% penetration in rat oral mucosa, and penetrated to approximately 120–200 μm; in vitro, more than 80% of Rhodamine 6G released within 5 min and complete release occurred at 30 min, while in vivo retention lasted up to 150 min versus negligible topical residue at 30 min.
- Against *Porphyromonas gingivalis*, Mino-DMN produced inhibition zones of 3.32 ± 0.26 cm at 2 days and 3.47 ± 0.31 cm at 7 days; no inhibition zones appeared in blank-DMN or control groups.
- In periodontitis rats, Mino-DMN reduced gingival index, decreased pro-inflammatory factors (IFN-γ, IL-1β, TNF-α), increased anti-inflammatory factors (TGF-β1, IL-10), improved bone parameters, increased osteogenic gene expression (COL1A1, OCN, RUNX2, BMP-2), and lowered osteoclastogenic gene expression compared with untreated, blank-DMN, and topical minocycline groups; compared with Periocline®, most indicators did not differ significantly, except ABL was significantly higher in the Mino-DMN group.
Methods
- Fabrication used a PDMS mold with a 10 × 10 array (300 μm backing side length, 800 μm spacing, 1000 μm height) and a two-step casting micro-molding process: a minocycline/gelatin solution was vacuum dried at 37°C to form tips, then a sucrose-blended HA solution was cast as the backing and freeze-dried.
- Characterization included stereo and fluorescence microscopy, SEM, tensile mechanical testing, ex vivo penetration into rat oral mucosa, in vitro drug release in PBS at 37°C, in vivo fluorescence imaging in SD rats, and Kirby-Bauer antibacterial testing against *P. gingivalis* ATCC33277.
- Animal study: 42 male SD rats (3 weeks old, 80–100 g) were randomized into 7 groups—Control, PD, UT, Mino-DMN (50 μg minocycline, every other day for 4 doses), Blank-DMN, Perio® (2.5 mg Periocline® ointment, every other day for 4 doses), and Mino-Topical (200 μg minocycline topical application, every other day for 4 doses); periodontitis was induced by ligature plus *P. gingivalis* inoculation, and outcomes were assessed by micro-CT, HE staining, qRT-PCR, and ELISA with two-tailed Student’s t-test or one-way ANOVA.
Limitations
- Stated by the paper: potential biases in animal experiments may explain the ABL disparity with Periocline®, and the relatively mild periodontal lesions in rats may have made tooth mobility differences less obvious.
- Evident from the text: the study is limited to a rat model with no human clinical data; sample sizes are small for several assays (e.g., n = 3 for micro-CT, ELISA, and qRT-PCR; n = 6 for clinical measures); treatment follow-up was 4 weeks; and minocycline was used as a model drug, with no long-term safety, scalability, or patient self-administration outcomes reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
5 Valid · 2 Not valid · 15 Not checked · 85 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Both in‐development minocycline formulations and clinically utilized medications currently necessitate specialized delivery devices for administration into periodontal pockets.”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > INTRODUCTION
What the sources say
- Partly supportedcites [27] Ma Y, Song J, Almassri HNS, et al. Minocycline‐loaded PLGA electrospun membrane prevents alveolar bone loss in experimental peridontitis. Drug Deliv. 2020; 27(1): 151‐ 160. 31913739 PMC6968699 sourceExperimental — accuracy not yet measured
The Discussion (p. n/a) supports the clinically-utilised half of the claim: Periocline® is described as 'a bio-absorbable drug in the form of a sustained local drug delivery system' whose usual clinical administration is 'weekly injections in the periodontal pocket for one month', and the Introduction notes that 'local drug delivery systems to provide a sustained release of antimicrobial agents in the periodontal pockets' have been investigated, with sub-antimicrobial local delivery pursued to avoid high local antibiotic concentrations. However, our copy nowhere states that these formulations *necessitate specialized delivery devices*: its stated limitations of the existing and emerging systems are non-constant release kinetics (80–90% of MINO released in 2–3 d), fluctuating pocket concentrations and repeated visits, and the in-development works it cites (Yang et al. 2018 in situ cubic liquid crystal; Liu et al. 2013 liposome controlled-release gel) are themselves the delivery carriers rather than examples said to require a separate device. The 'in-development formulations ... necessitate specialized delivery devices' element is therefore not attributable to this source. (LLM, conf=0.68)
- Supportedcites [28] Zhang T, Qiu Y, Song J, Zhou P, Wu X. Electrosprayed minocycline hydrochloride‐loaded microsphere/SAIB hybrid depot for periodontitis treatment. Drug Deliv. 2021; 28(1): 620‐ 633. 33779441 PMC8008938 source
The Introduction states that 'recent studies have focused on local application associated with the minimal inhibitory concentration of MINO and a sustained-release device in order to avoid these adverse effects caused by high local concentration of antibiotics', i.e. in-development minocycline systems (the authors' PLGA electrospun membrane, the microsphere/SAIB depot) are carriers required for intra-pocket use. The Discussion covers the clinically utilized medication the same way: Periocline® is 'a bio-absorbable sustained local drug delivery system containing 20 mg/g MINO ... usually administered by injection into the periodontal pocket once a week', and the Methods describe injecting M-SAIB/MINO-M-SAIB or Periocline® into the periodontal pockets. The Discussion adds that the injectable depot 'will be easier to place ... in the periodontal pockets than membranes', so both halves of the claim (in-development and clinically used minocycline products needing a dedicated delivery system for pocket administration) are carried by our copy. (LLM, conf=0.82)
- Not checked yetcites [29] Zhiqing P, Peicheng X, Jingjing Z, et al. Local delivery of minocycline‐loaded PEG‐PLA nanoparticles for the enhanced treatment of periodontitis in dogs. Int J Nanomedicine. 2014; 9: 3963‐ 3970. 25170266 PMC4145825
- Could not verifycites [30] Choi EH, Um HS, Chang BS, Lee SY, Lee JK. Clinical and microbiological effects of adjunctive local delivery of minocycline (Periocline) in patients receiving supportive periodontal therapy: a pilot study. J Periodontal Implant Sci. 2021; 51(1): 53‐ 62. 33634615 PMC7920842 sourceExperimental — accuracy not yet measured
Our copy of Choi et al. (2021) discusses minocycline formulations used subgingivally — a sustained-action 2% ointment (INTRODUCTION), the microcapsule gel Periocline® and controlled-release/minocycline microspheres (Treatment regimen; refs 19–21) — but no passage states or implies that these formulations require specialized delivery devices. Searched: 'specialized delivery device/applicator/syringe/carrier', 'in-development minocycline formulation', 'administration into periodontal pockets'; the closest passages (Treatment regimen, p. null; INTRODUCTION) describe the gel as 'applied directly into periodontal pockets after subgingival debridement' without reference to any device requirement, and the paper is not truncated. The claim's decisive point (device necessity, and for in-development formulations) is therefore not addressed by this source. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Minocycline, known for its broad‐spectrum antibacterial activity against periodontal pathogens, is a commonly used antibiotic in the treatment of periodontal disease. 23”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > INTRODUCTION
What the sources say
- Partly supportedcites [23] Okamoto‐Shibayama K, Sekino J, Yoshikawa K, Saito A, Ishihara K. Antimicrobial susceptibility profiles of oral treponema species. Anaerobe. 2017; 48: 242‐ 248. 29030100 sourceExperimental — accuracy not yet measured
Our copy (the 歯科学報 Vol.119 No.6 (2019) doctoral-thesis summary of the Anaerobe 48:242-248 paper, pp. 538-539) states in 論文内容の要旨 §3 that minocycline (MINO), together with DOXY, AZM, EM and CLDM, showed low MIC (≤1 μg/mL) — so the drug is active against the organisms tested. But the panel of organisms was only 7 strains of three oral Treponema species (T. denticola ATCC 35404/35405/35520/35521/GM-1, T. socranskii ATCC 35536, T. vincentii ATCC 35580), and the stated aim (§1) is to fill the gap in susceptibility data for oral treponemes among periodontal pathogens; the paper therefore does not establish 'broad-spectrum' activity against periodontal pathogens in general (no P. gingivalis, A. actinomycetemcomitans etc.). The accompanying assertion that minocycline is commonly used to treat periodontal disease is also not made here — the 論文審査の要旨 (p. 538) discussion of antibiotic use in periodontitis recommends azithromycin, the agent whose effect was noted, not minocycline. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recently, MNs have shown great promise for the delivery of drugs to oral tissues, particularly for treating periodontitis.”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > INTRODUCTION
What the sources say
- Supportedcites [36] Zhang X, Hasani‐Sadrabadi MM, Zarubova J, et al. Immunomodulatory microneedle patch for periodontal tissue regeneration. Matter. 2022; 5(2): 666‐ 682. 35340559 PMC8942382 source
The paper is itself a demonstration of microneedles delivering drugs to oral (gingival/periodontal) tissue for periodontitis: the Abstract states the modular MN patch 'delivered both antibiotic and cytokines into the local gingival tissue' and that in vivo delivery 'suppressed proinflammatory factors and promoted pro-regenerative signals and tissue healing, which demonstrated the therapeutic potential of local immunomodulation for tissue regeneration.' The INTRODUCTION frames MN patches as addressing local, sustained drug delivery in the oral cavity (noting MNs have been employed for transdermal, ocular, vascular and mucosal delivery, refs 20-21), and the DISCUSSION extends the patch beyond gingivitis/periodontitis to other oral problems such as canker sores. This is a broad background statement and our copy clearly treats the topic that way; the only element not literally asserted is the field-wide 'recently ... great promise' framing, which the paper's own results and design rationale carry. (LLM, conf=0.85)
- Supportedcites [37] Song C, Zhang X, Lu M, Zhao Y. Bee sting‐inspired inflammation‐responsive microneedles for periodontal disease treatment. Research. 2023; 6: 119. PMC10202374 37223473 source
The Discussion (p. Discussion) states that drug-laden microcarriers including MNs "are initially showing promise in the treatment of periodontal diseases" and that "MN-based periodontal treatments have considerable potential." The Results (p. Results) report that in the rat oral cavity the MNs penetrated the gingival into the gingival sulcus and conclude "MNs could be an ideal way to treat periodontal disease," with added penetration of buccal mucosa and tongue indicating wider oral application. The Introduction (p. Introduction) frames the work as local drug delivery of MNs to oral tissue for periodontal disease, matching the citing sentence's paraphrase. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“aiding in alleviating local swelling, pain, and discomfort induced by inflammation”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > Drug loading and release study of the DMN patch
What the sources say
- Not checked — no full text of the sourcecites [39] Almazin SM, Dziak R, Andreana S, Ciancio SG. The effect of doxycycline Hyclate, chlorhexidine gluconate, and minocycline hydrochloride on osteoblastic proliferation and differentiation in vitro. J Periodontol. 2009; 80(6): 999‐ 1005. 19485832 source
- Not checked — no full text of the sourcecites [44] Collins MN, Birkinshaw C. Hyaluronic acid based scaffolds for tissue engineering – a review. Carbohydr Polym. 2013; 92(2): 1262‐ 1279. 23399155 source
- Could not verifycites [45] Colangelo MT, Belletti S, Govoni P, Guizzardi S, Galli C. A biomimetic polynucleotides–hyaluronic acid hydrogel promotes wound healing in a primary gingival fibroblast model. Appl Sci. 2021; 11(10): 4405. sourceExperimental — accuracy not yet measured
Our copy of Colangelo et al. (2021) describes hyaluronic acid only as a biocompatible ECM-mimicking scaffold that maintains tissue structure and volume, has good tolerability and ease of use (Introduction, refs [7]-[11]), and as a component of granulation tissue providing a provisional matrix that facilitates fibroblast migration (Discussion). No passage states that HA alleviates local swelling, pain or discomfort caused by inflammation; the study is an in vitro gingival fibroblast assay measuring proliferation, migration, collagen and proteoglycan deposition, with no symptom or inflammatory-outcome measures. Searched: 'hyaluronic acid alleviates swelling pain discomfort inflammation', 'anti-inflammatory effect of hyaluronic acid edema pain relief', 'swelling edema pain symptoms patients relief' — the only inflammation-related hits are reference titles ([15] Polydeoxyribonucleotide Regulation of Inflammation; [16] Key Role of DAMP in Inflammation), not statements about HA. (LLM, conf=0.70)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Minocycline has been demonstrated to inhibit local inflammatory responses by downregulating the production of inflammatory factors such as TNF‐α. 46”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > In vivo studies of minocycline MNs for periodontitis treatment
What the sources say
- Partly supportedcites [46] Orylska‐Ratynska M, Placek W, Owczarczyk‐Saczonek A. Tetracyclines—an important therapeutic tool for dermatologists. Int J Environ Res Public Health. 2022; 19(12): 7246. 35742496 PMC9224192 sourceExperimental — accuracy not yet measured
Section 2.2 Anti-Inflammatory Activity states the substance of the claim but at the level of the whole class: tetracyclines 'reduce the production of pro-inflammatory cytokines by neutrophils, such as interleukin-1β (IL-1β), IL-8, and tumor necrosis factor-α', and inhibit leukocyte migration and iNOS/NO. The dedicated minocycline section (3.4) covers only its lipophilicity, blood–brain barrier penetration, acne dosing and long-term adverse effects, and makes no mention of TNF-α or cytokine downregulation, so the specific attribution to minocycline as the demonstrated agent is not supported by our copy. (LLM, conf=0.72)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
54 more claims · 1 with their cited sources checked
Create a free account to see all 107 claims and to verify the 24 references still open.
- It may state two separate claims as one. 42
- Probably not a substantial claim. 8
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Applying this technology to deliver MNC topically reduces the systemic exposure and bacterial resistance without affecting the normal flora in the gastrointestinal tract. Also, avoids the problematic adverse effects of this drug and enhances the bioavailability due to eliminating the first pass metabolism [27,28,29,30].”
From Formulation and Characterization of PLGA Minocycline Microneedles for Enhanced Skin Deposition and Antibacterial Activity in Acne Treatment (2025) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > Drug loading and release study of the DMN patch
“In vitro drug release study of the DMN patch involved immersing the patch in PBS at 37°C, while continuously tracking the fluorescence emitted by Rhodamine 6G, a model drug in the DMN patch.”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > MATERIALS AND METHODS > Drug release in vitro and dissolution behavior of the DMN patch
“The drug release study was performed using fluorescein‐loaded DMN patch.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > Mechanical property of the Mino‐DMN patch
“We also observed that Rhodamine 6G was successfully delivered to the inner wall of the created microholes, with the majority of fluorescence concentrated inside the microholes (Figure 1e,f).”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > Fabrication and characterization of the Mino‐DMN patch
“(e–g) Scanning electron micrograph images of minocycline‐loaded DMN patch with porous HA patch backing; In f and g, the DMN patch was vertically cut open to expose its patch backing pores.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > In vivo studies of minocycline MNs for periodontitis treatment
“Additionally, osteoclastogenic genes like NFATc1 and MMP‐2 showed notably lower expression.”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > In vivo studies of minocycline MNs for periodontitis treatment
“The expression levels of (f) MMP‐8, (g) Cathepsin K, (h) NFATc1, (i) BMP‐2, (j) RUNX2, (k) COL1A1, and (l) OCN in the alveolar bone of rats in each group were analyzed using q‐PCR method.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > MATERIALS AND METHODS > Drug release and degradability of the DMN patch in vivo
“In vivo drug release experiments of the DMN patches containing Rhodamine 6G (50 μg) were conducted in SD rats.”
§ Facile minocycline deployment in gingiva using a dissolvable microneedle patch for the adjunctive treatment of periodontal disease > RESULTS AND DISCUSSION > Drug loading and release study of the DMN patch
“(b) Topical application of fluorescein and fluorescein DMN quantified the fluorescence intensity in the gingiva.”
Citations
Cites
Pihlstrom, B. L., Michalowicz, B. S., & Johnson, N. W. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67728-8 · Cited by 3,522
Hyaluronic acid based scaffolds for tissue engineering—A review
Collins, M. N., & Birkinshaw, C. (2013) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2012.10.028 · Cited by 1,092
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
The cytokine network involved in the host immune response to periodontitis
Pan, W., Wang, Q., & Chen, Q. (2019) · International Journal of Oral Science · doi:10.1038/s41368-019-0064-z · Cited by 696
Strengthening the Prevention of Periodontal Disease: The WHO Approach
Petersen, P. E., & Ogawa, H. (2005) · Journal of Periodontology · doi:10.1902/jop.2005.76.12.2187 · Cited by 532
Chang, H., Zheng, M., Yu, X., Than, A., Seeni, R. Z., Kang, R., Tian, J., Khanh, D. P., Liu, L., Chen, P., et al. (2017) · Advanced Materials · doi:10.1002/adma.201702243 · Cited by 462
Self-citationHaney, E., Trimble, M., Cheng, J., Vallé, Q., & Hancock, R. (2018) · Biomolecules · doi:10.3390/biom8020029 · Cited by 308
Regenerative Medicine for Periodontal and Peri-implant Diseases
Larsson, L., Decker, A. M., Nibali, L., Pilipchuk, S. P., Berglundh, T., & Giannobile, W. V. (2016) · Journal of Dental Research · doi:10.1177/0022034515618887 · Cited by 300
How is the development of dental biofilms influenced by the host?
Marsh, P. D., & Devine, D. A. (2011) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2010.01673.x · Cited by 264
Microneedle biomedical devices
Zheng, M., Sheng, T., Yu, J., Gu, Z., & Xu, C. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00141-6 · Cited by 235
Cited by
Liu, J., Zheng, W., Sun, H., González, F. E., Zhou, D., & Xu, X. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114402 · Cited by 20
Bioinspired hydrogel for sustained minocycline release: A superior periodontitis solution
Liu, S., Zheng, W., Wang, L., Zhang, Y., Feng, K., Zhang, Y., Yang, H., Xiao, Y., Sun, C., Liu, X., et al. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101638 · Cited by 16
Self-citationGong, H., Ma, S., Wang, B., Liu, Y., Xiao, H., Wang, Y., Sun, D., Su, Y., Wang, J., & Zhao, J. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102494 · Cited by 7
Zheng, Y., Xie, Y., Dong, X., Shen, S., Zheng, G., Weng, J., & Yan, Q. (2025) · ACS Applied Polymer Materials · doi:10.1021/acsapm.5c01387 · Cited by 6
Li, W., Zhang, D., Huang, H., Zou, R., Zhang, Z., Sun, P., Chen, H., Yang, L., Jiang, S., & Zeng, X. (2026) · ACS Nano · doi:10.1021/acsnano.5c19988 · Cited by 6
Abu Ershaid, J. M., Abudoleh, S. M., Lafi, D. N., & Dahshan, N. A. (2025) · Polymers · doi:10.3390/polym17212912 · Cited by 5
Sun, J., Zhao, B., Wo, K., Xia, Y., Liu, Y., Li, S., Yang, C., Liu, S., & Ding, Y. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113868 · Cited by 5
Zhang, Y., Zhang, J., Wang, B., Wang, X., Bai, H., & Cheng, X. (2026) · Journal of Water Process Engineering · doi:10.1016/j.jwpe.2026.110507 · Cited by 5
Self-citationMicroneedle patches with antimicrobial and immunomodulating properties for periodontal regeneration
Wang, B., Gong, H., Jiang, Y., Song, A., Wang, J., & Li, M. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114168 · Cited by 4
Li, Y., Jin, Y., Huang, L., Feng, J., & Ren, Q. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108329 · Cited by 1
Microneedles for treatment of oral diseases: A comprehensive review
Wu, W., Dai, T., Wang, B., Zhang, H., Xu, Q., Lin, Y., Sun, F., Wang, J., Hu, T., Xia, Y., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108701 · Cited by 1
Kornicka, J., Śniadek, P., & Rafał, W. (2026) · Advanced Materials Technologies · doi:10.1002/admt.202502478
Peng, B., Yang, J., Lin, R., Han, Y., Wang, H., Zhou, R., Yan, T., Liu, S., Jiang, H., Li, Y., et al. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04609-6
Microneedle technologies in emerging strategies for non-transdermal drug delivery
Simoes, L., Mendes, M., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2026) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2026.127102
Xiang, Y., Gong, Z., Liu, J. X., Zhu, Y., Zhang, Z., Li, B., Luo, J., Su, M., & Yeung, K. (2026) · Bioactive Materials · doi:10.1016/j.bioactmat.2026.07.013
Zhang, R., Zeng, Y., Lin, L., Jin, L., & Li, D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080927
Patiyananuwat, N., Thanapongpibul, C., Chinavinijkul, P., Phumkrachai, B., Ngamwongronnachai, C., Tancharoen, S., & Nasongkla, N. (2026) · RSC Advances · doi:10.1039/d6ra05856f
Metadata
- Authors
- Li, H., Wen, X., Gong, X., Wu, Y., Zhao, P., Zhang, Y., Sha, Z., Chang, H., & Chen, X.
- Affiliations
- Zhejiang University Medical College Affiliated Stomatological Hospital (CN)
- Hangzhou Institute of Medicine, Chinese Academy of Sciences (CN)
- Corresponding author
- Chang, Hao
- Chen, Xuepeng
- Venue
- Bioengineering & Translational Medicine
- Publisher
- Wiley
- Published
- 2024-10-20
- Volume
- 10
- Issue
- 2
- Pages
- e10730-e10730
- ISSN
- 2380-6761 (ISSN-L)
- PMC
- PMC11883109
- OpenAlex
- W4403615471
- Semantic Scholar
- 62cce9673d03e291b78abf39bab078c9b4928422
- Cited by
- 17
- References
- 49
- Citations by year
- 2026: 10 · 2025: 7
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bioengineering & Translational Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (81400511, 82020108011, 82202329)
- Natural Science Foundation of Zhejiang Province (LY18H140001)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Keywords
- minocycline, periodontitis, local drug delivery, freeze-drying, vacuum drying, bone formation, anti-inflammatory activity, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-15, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-15 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.